The TAPER (Tailored Adjuvant therapy in POLE-mutated and p53 wildtype early-stage Endometrial cancer) is a multicenter, single-arm, prospective cohort study, which is specifically investigating treatment reductions in patients affected by early stage POLE-mutated/p53-wild-type EC with non-specific molecular profile (NSMP) (54). The gene discussed is TP53; the disease is endometrial cancer.